StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a research report issued on Monday. The firm set a “sell” rating on the stock.
Bio-Path Stock Performance
Shares of BPTH stock opened at $0.71 on Monday. The business has a fifty day moving average of $0.94 and a 200 day moving average of $1.43. Bio-Path has a 1 year low of $0.61 and a 1 year high of $12.00.
Institutional Investors Weigh In On Bio-Path
An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC bought a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path as of its most recent SEC filing. Hedge funds and other institutional investors own 5.74% of the company’s stock.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Articles
- Five stocks we like better than Bio-Path
- What is the Hang Seng index?
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- 10 Best Airline Stocks to Buy
- Netflix Is On Track To Hit $1,000 By Christmas
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
